Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anaesthetic agents and electroconvulsive therapy efficacy in severe unipolar depression
2025-524829-40-00Phase 4Authorised
- Sponsor
- Varsinais-Suomen hyvinvointialue
- Start
- Sep 2026
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of propofol, etomidate, methohexital and succinylcholine in major depressive disorder (MDD) (3 arms), sponsored by Varsinais-Suomen hyvinvointialue. Primary endpoint: Time to first clinical response. Planned start Sep 2026; status: authorised.
02
Drugs
propofoletomidatemethohexitalsuccinylcholine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-524829-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524829-40-00.